Yuguang Wang
Yuguang Wang has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Samuel Chackalamannil
Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033
5 shared publicationsVilma Ruperto
Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033
4 shared publicationsZhiyong Hu
Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033
4 shared publicationsWilliam Greenlee
Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA
3 shared publicationsGordon Crosby
Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033
2 shared publicationsHerbert Binch
2 shared publications
Latest Publications
- 1 July 2009
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 15 (19) , 2262-2269
The Role of Exploratory Drug Metabolism and Pharmacokinetics in New Drug Research: Case Study-Selection of a Thrombin Receptor Antagonist for Development
The rising costs and time associated with bringing new medicines to the market have created a need for a new paradigm for reducing the attrition rates of drug candidates in both preclinical and clinical development stages. Early appraisal of drug metabolism and pharmacokinetic (DMPK) parameters is now possible due to several higher throughput in vitro and in vivo screens. This knowledge of DMPK properties should not only shorten the timelines for the selection of drug candidates but also enhance the probability of their success for development. The role of DMPK researchers in the drug research paradigm should not be limited to screening a large array of compounds during the lead optimization process but should include a strive for an understanding of the absorption, distribution, metabolism, excretion, and potential drug-related toxicities of a chemical series. As an example, in this article we present a specific DMPK research screening paradigm and describe a case study using the Thrombin Receptor Antagonist program. This screening paradigm followed by the extensive lead optimization process culminated in the selection of SCH 530348, a potent, selective and orally active thrombin receptor antagonist for the treatment of thrombosis.
- 1 July 2009
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 15 (19) , 2262-2269
The Role of Exploratory Drug Metabolism and Pharmacokinetics in New Drug Research: Case Study-Selection of a Thrombin Receptor Antagonist for Development
The rising costs and time associated with bringing new medicines to the market have created a need for a new paradigm for reducing the attrition rates of drug candidates in both preclinical and clinical development stages. Early appraisal of drug metabolism and pharmacokinetic (DMPK) parameters is now possible due to several higher throughput in vitro and in vivo screens. This knowledge of DMPK properties should not only shorten the timelines for the selection of drug candidates but also enhance the probability of their success for development. The role of DMPK researchers in the drug research paradigm should not be limited to screening a large array of compounds during the lead optimization process but should include a strive for an understanding of the absorption, distribution, metabolism, excretion, and potential drug-related toxicities of a chemical series. As an example, in this article we present a specific DMPK research screening paradigm and describe a case study using the Thrombin Receptor Antagonist program. This screening paradigm followed by the extensive lead optimization process culminated in the selection of SCH 530348, a potent, selective and orally active thrombin receptor antagonist for the treatment of thrombosis.
- 5 November 2002
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 45 (25) , 5415-5418
Improving the Oral Efficacy of CNS Drug Candidates: Discovery of Highly Orally Efficacious Piperidinyl Piperidine M2 Muscarinic Receptor Antagonists
In search of a backup M2 muscarinic receptor antagonist to the previously reported compound 1, we discovered compound (+)-14, which showed superior oral efficacy in animal models. The improvement of oral efficacy was achieved by modulating both the molecular weight and lipophilicity of the lead compounds.
- 5 November 2002
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 45 (25) , 5415-5418
Improving the Oral Efficacy of CNS Drug Candidates: Discovery of Highly Orally Efficacious Piperidinyl Piperidine M2 Muscarinic Receptor Antagonists
In search of a backup M2 muscarinic receptor antagonist to the previously reported compound 1, we discovered compound (+)-14, which showed superior oral efficacy in animal models. The improvement of oral efficacy was achieved by modulating both the molecular weight and lipophilicity of the lead compounds.
- 1 November 2002
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 12 (21) , 3149-3152
Design and synthesis of xanthine analogues as potent and selective PDE5 inhibitors
- 1 November 2002
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 12 (21) , 3149-3152
Design and synthesis of xanthine analogues as potent and selective PDE5 inhibitors
- 4 March 2002
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 12 (7) , 1087-1091
Sulfide analogues as potent and selective M 2 muscarinic receptor antagonists
- 4 March 2002
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 12 (7) , 1087-1091
Sulfide analogues as potent and selective M 2 muscarinic receptor antagonists
- 27 March 2001
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 11 (7) , 891-894
Design and synthesis of ether analogues as potent and selective M2 muscarinic receptor antagonists
- 27 March 2001
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 11 (7) , 891-894
Design and synthesis of ether analogues as potent and selective M2 muscarinic receptor antagonists
- 1 October 2000
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 10 (20) , 2247-2250
Design and synthesis of piperidinyl piperidine analogues as potent and selective M2 muscarinic receptor antagonists
- 1 October 2000
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 10 (20) , 2247-2250
Design and synthesis of piperidinyl piperidine analogues as potent and selective M2 muscarinic receptor antagonists